Prevalence and Predictors of Neoadjuvant Therapy for Stage IIIA Non-Small Cell Lung Cancer in the National Cancer Database: Importance of Socioeconomic Status and Treating Institution

被引:18
|
作者
Sher, David J. [1 ]
Liptay, Michael J. [2 ]
Fidler, Mary Jo [3 ]
机构
[1] Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Cardiothorac Surg, Chicago, IL 60612 USA
[3] Rush Univ, Med Ctr, Sect Med Oncol, Chicago, IL 60612 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 89卷 / 02期
关键词
RANDOMIZED-TRIAL; PHASE-II; PREOPERATIVE CHEMOTHERAPY; RACIAL-DIFFERENCES; RADIATION-THERAPY; ONCOLOGY-GROUP; RADIOTHERAPY; SURGERY; CHEMORADIATION; CARCINOMA;
D O I
10.1016/j.ijrobp.2014.01.033
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The optimal locoregional therapy for stage IIIA non-small cell lung cancer (NSCLC) is controversial, with definitive chemoradiation therapy (CRT) and neoadjuvant therapy followed by surgery (NT-S) serving as competing strategies. In this study, we used the National Cancer Database to determine the prevalence and predictors of NT in a large, modern cohort of patients. Methods and Materials: Patients with stage IIIA NSCLC treated with CRT or NT-S between 2003 and 2010 at programs accredited by the Commission on Cancer were included. Predictors were categorized as clinical, time/geographic, socioeconomic, and institutional. In accord with the National Cancer Database, institutions were classified as academic/research program and as comprehensive and noncomprehensive community cancer centers. Logistic regression and random effects multilevel logistic regression were performed for univariable and multivariable analyses, respectively. Results: The cohort consisted of 18,581 patients, 3,087 (16.6%) of whom underwent NT-S (10.6% induction CRT, 6% induction chemotherapy). The prevalence of NT-S was constant over time, but there were significant relative 31% and 30% decreases in pneumonectomy and right-sided pneumonectomy, respectively, over time (P trend <.02). In addition to younger age, lower T stage, and favorable comorbidity score, indicators of higher socioeconomic status were strong independent predictors of NT-S, including white race, higher income, and private/managed insurance. The type of institution (academic/research program vs comprehensive or noncomprehensive community cancer centers, odds ratio 1.54 and 2.08, respectively) strongly predicted NT-S, but treatment volume did not. Conclusions: Neoadjuvant therapy followed by surgery was an uncommon treatment approach in Commission on Cancer programs, and the prevalence of postinduction pneumonectomy decreased over time. Higher socioeconomic status and treatment at academic institutions were significant predictors of NT-S. Further research should be performed to enable a better understanding of these disparities. (C) 2014 Elsevier Inc.
引用
收藏
页码:303 / 312
页数:10
相关论文
共 50 条
  • [41] Neoadjuvant chemotherapy for non-small cell lung cancer
    Pinder-Schenck, M.
    Bepler, G.
    MINERVA CHIRURGICA, 2009, 64 (06) : 611 - 628
  • [42] Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer
    Yeh, Justin
    Marrone, Kristen A.
    Forde, Patrick M.
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S451 - S459
  • [43] Five-year survival of resectable stage IIIA non-small cell lung cancer in Brazil
    de Barros, Maria Laura Gritti Paes
    Silva, Vinicius G.
    Moreira, Frederico Rafael
    Perez, Stela V.
    Younes, Riad N.
    Abrao, Fernando Conrado
    JOURNAL OF SURGICAL ONCOLOGY, 2023, 128 (07) : 1195 - 1204
  • [44] Neoadjuvant therapy for resectable non-small cell lung cancer
    Welcker, Katrin
    Jonigk, Danny
    Kropf-Sanchen, Cornelia
    Tufman, Amanda
    Draube, Andreas
    Stenzinger, Albrecht
    Zaatar, Mohamed
    Thomas, Michael
    PNEUMOLOGIE, 2025, 79 (01): : 16 - 24
  • [45] Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer
    Donington, Jessica S.
    Paulus, Rebecca
    Edelman, Martin J.
    Krasna, Mark J.
    Le, Quynh-Thu
    Suntharalingam, Mohan
    Loo, Billy W., Jr.
    Hu, Chen
    Bradley, Jeffrey D.
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2020, 160 (05) : 1331 - +
  • [46] Trimodal therapy and surgical approaches in stage IIIA/N2 non-small cell lung cancer
    Hu, Pin-Ching
    Huang, Jing-Yang
    Cheng, Ya-Fu
    Cheng, Ching-Yuan
    Huang, Chang-Lun
    Hung, Wei-Heng
    Wang, Bing-Yen
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [47] Neoadjuvant Pembrolizumab for Early Stage Non-Small Cell Lung Cancer
    Bar, J.
    Urban, D.
    Redinsky, I.
    Ackerstein, A.
    Daher, S.
    Kamer, I.
    Onn, A.
    Shulimzon, T.
    Peled, M.
    Zeitlin, N.
    Kremer, R.
    Raskin, S.
    Ben-Nun, A.
    Perelman, M.
    Ofek, E.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S865 - S866
  • [48] Are we treating enough elderly patients with early stage non-small cell lung cancer?
    Pallis, A. G.
    Scarci, M.
    LUNG CANCER, 2011, 74 (02) : 149 - 154
  • [49] Neoadjuvant chemotherapy for early stage non-small cell lung cancer
    Beitler, AL
    Urschel, JD
    Takita, H
    MEDICAL SCIENCE RESEARCH, 1998, 26 (12): : 853 - 854
  • [50] Prognostic factors and long term results of neo adjuvant therapy followed by surgery in stage IIIA N2 non-small cell lung cancer patients
    Li, Jing
    Dai, Chun-Hua
    Shi, Shun-Bing
    Chen, Ping
    Yu, Li-Chao
    Wu, Jian-Rong
    ANNALS OF THORACIC MEDICINE, 2009, 4 (04) : 201 - 207